A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection
Clinical trial NCT04969172 · UNKNOWN
Trial details
- NCT number
- NCT04969172
- Sponsor
- Eli Sprecher, MD
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-11
- Primary completion
- 2022-07-11
- Enrollment
- 155
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.